Elimination of neuroblastoma and small-cell lung cancer cells with an anti-neural cell adhesion molecule immunotoxin

Journal of the National Cancer Institute

Volumn 88, Issue 16, 1996, Pages 1136-1145

  Roy, Denis C ^a,c   Ouellet, Sophie ^a   Le Houillier, Christiane ^a   Ariniello, Pamela D ^b   Perreault, Claude ^a   Lambert, John M ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b IMMUNOGEN INC   (United States)

^c UNIVERSITY OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOTOXIN; MONOCLONAL ANTIBODY; NERVE CELL ADHESION MOLECULE;

ARTICLE; BONE MARROW SUPPRESSION; CELL SPECIFICITY; CONTROLLED STUDY; CYTOTOXICITY; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; LUNG SMALL CELL CANCER; NEUROBLASTOMA; STEM CELL TRANSPLANTATION;

EID: 0029822956     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.16.1136     Document Type: Article

References (39)

1. Vallera DA. Immunotoxins: will their clinical promise be fulfilled? [editorial]. Blood 1994;83:309-17.
2. Pastan IH, Pai LH, Brinkmann U, Fitzgerald DJ. Recombinant toxins: new therapeutic agents for cancer. Ann N Y Acad Sci 1995;758:345-54.
3. Aletsee-Ufrecht MC, Langley K, Rotsch M, Havemann K, Gratzl M. NCAM: a surface marker for human small cell lung cancer cells. FEBS Lett 1990;267:295-300.
4. Rygaard K, Moller C, Bock E, Spang-Thomsen M. Expression of cadherin and NCAM in human small cell lung cancer cell lines and xenografts. Br J Cancer 1992;65:573-7.
5. Kibbelaar RE, Moolenaar KE, Michalides RJ, Bitter-Suermann D, Addis BJ, Mooi WJ. Expression of the embryonal neural cell adhesion molecule N-CAM in lung carcinoma. Diagnostic usefulness of monoclonal antibody 735 for the distinction between small cell lung cancer and non-small cell lung cancer. J Pathol 1989;159:23-8.
6. Carbone DP, Koros AM, Linnoila RI, Jewett P, Gazdar AF. Neural cell adhesion molecule expression and messenger RNA splicing patterns in lung cancer cell lines are correlated with neuroendocrine phenotype and growth morphology. Cancer Res 1991;51:6142-9.
7. Roth J, Zuber C, Wagner P, Blaha I, Bitter-Suermann D, Heitz PU. Presence of the long chain form of polysialic acid of the neural cell adhesion molecule in Wilms' tumor. Identification of a cell adhesion molecule as an oncodevelopmental antigen and implications for tumor histogenesis. Am J Pathol 1988;133:227-40.
8. Figarella-Branger DF, Durbec PL, Rougon GN. Differential spectrum of expression of neural cell adhesion molecule isoforms and L1 adhesion molecules on human neuroectodermal tumors. Cancer Res 1990;50:6364-70.
9. Patel K, Bourne S, Phimister B, Coakham H, Kemshead JT. Presence of neural cell adhesion molecule on human embryonic and brain tumours. Biochem Soc Trans 1990;18:408-10.
10. Griffin JD, Hercend T, Beveridge R, Schlossman SF. Characterization of an antigen expressed by human natural killer cells. J Immunol 1983; 130:2947-51.
11. Stahel RA, Gilks WR, Schenker T. Antigens of lung cancer: results of the Third International Workshop on Lung Tumor and Differentiation Antigens. J Natl Cancer Inst 1994;86:669-72.
12. Hida T, Koike K, Sekido Y, Nishida K, Sugiura T, Ariyoshi Y, et al. Epitope analysis of cluster 1 and NK cell-related monoclonal antibodies. Br J Cancer Suppl 1991;14:24-8.
13. Lambert JM, McIntyre G, Gauthier MN, Zullo D, Rao V, Steeves RM, et al. The galactose-binding sites of the cytotoxic lectin ricin can be chemically blocked in high yield with reactive ligands prepared by chemical modification of glycopeptides containing triantennary N-linked oligosaccharides. Biochemistry 1991;30:3234-47.
14. Lambert JM, Goldmacher VS, Collinson AR, Nadler LM, Blattler WA. An immunotoxin prepared with blocked ricin: a natural plant toxin adapted for therapeutic use. Cancer Res 1991;51(23 Pt 1):6236-42.
15. Goldmacher VS, Lambert JM, Blattler WA. The specific cytotoxicity of immunoconjugates containing blocked ricin is dependent on the residual binding capacity of blocked ricin: evidence that the membrane binding and A-chain translocation activities of ricin cannot be separated. Biochem Biophys Res Commun 1992;183:758-66.
16. Smith A, Waibel R, Westera G, Martin A, Zimmerman AT, Stahel RA. Immunolocalisation and imaging of small cell cancer xenografts by the IgG2a monoclonal antibody SWA11. Br J Cancer 1989;59:174-8.
17. Roy DC, Perreault C, Belanger R, Gyger M, Le Houillier C, Blattler WA, et al. Elimination of B-lineage leukemia and lymphoma cells from bone marrow grafts using anti-B4-blocked-ricin immunotoxin. J Clin Immunol 1995;15:51-7.
18. Rice GE, Munro JM, Corless C, Bevilacqua MP. Vascular and nonvascular expression of INCAM-110. A target for mononuclear leukocyte adhesion in normal and inflamed human tissues. Am J Pathol 1991;138:385-93.
19. Roy DC, Tantravahi R, Murray C, Dear K, Gorgone B, Anderson KC, et al. Natural history of mixed chimerism after bone marrow transplantation with CD6-depleted allogeneic marrow: a stable equilibrium. Blood 1990; 75:296-304.
20. Collinson AR, Lambert JM, Liu Y, O'Dea C, Shah SA, Rasmussen RA, et al. Anti-CD6-blocked ricin: an anti-pan T-cell immunotoxin. Int J Immunopharmacol 1994;16:37-49.
21. Roy DC, Felix M, Cannady WG, Cannistra S, Ritz J. Comparative activities of rabbit complements of different ages using an in-vitro marrow purging model. Leuk Res 1990;14:407-16.
22. Taswell C. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J Immunol 1981;126:1614-9.
23. Iscove NN, Seiber F, Winterhalter KH. Erythroid colony formation in cultures of mouse and human bone marrow: analysis of the requirement for erythropoietin by gel filtration and affinity chromatography on agaroseconcanavalin A. J Cell Physiol 1974;83:309-20.
24. Derbyshire EJ, Stahel RA, Wawrzynczak EJ. Potentiation of a weakly active ricin A chain immunotoxin recognizing the neural cell adhesion molecule. Clin Exp Immunol 1992;89:336-40.
25. Zangemeister-Wittke U, Collinson AR, Frosch B, Waibel R, Schenker T, Stahel RA. Immunotoxins recognising a new epitope on the neural cell adhesion molecule have potent cytotoxic effects against small cell lung cancer. Br J Cancer 1994;69:32-9.
26. Johnson FL, Goldman S. Role of autotransplantation in neuroblastoma. Hematol Oncol Clin North Am 1993;7:647-63.
27. Stahel RA, Mabry M, Skarin AT, Speak J, Bernai SD. Determination of bone marrow metastasis in small-cell lung cancer by monoclonal antibody. J Clin Oncol 1985;3:455-61.
28. Humblet Y, Feyens AM, Sekhavat M, Agaliotis D, Canon JL, Symann ML. Immunological and pharmacological removal of small cell lung cancer cells from bone marrow autografts. Cancer Res 1989;49:5058-61.
29. Moss TJ, Reynolds CP, Sather HN, Romansky SG, Hammond GD, Seeger RC. Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. N Engl J Med 1991;324:219-26.
30. Graham-Pole J, Gee A, Emerson S, Gallo J, Lee C, Luzins J, et al. Myeloablative chemoradiotherapy and autologous bone marrow infusions for treatment of neuroblastoma: factors influencing engraftment. Blood 1991;78:1607-14.
31. Matthay KK, Atkinson JB, Stram DO, Selch M, Reynolds CP, Seeger RC. Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: a Childrens Cancer Group pilot study. J Clin Oncol 1993;11:2226-33.
32. Glorieux P, Bouffet E, Philip I, Biron P, Holzapfel L, Floret D, et al. Metastatic interstitial pneumonitis after autologous bone marrow transplantation. A consequence of reinjection of malignant cells? Cancer 1986;58:2136-9.
33. Rill DR, Santana VM, Roberts WM, Nilson T, Bowman LC, Krance RA, et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994; 84:380-3.
34. Moss TJ, Cairo M, Santana VM, Weinthal J, Hurvitz C, Bostrom B. Clonogenicity of circulating neuroblastoma cells: implications regarding peripheral blood stem cell transplantation. Blood 1994;83:3085-9.
35. Brugger W, Bross KJ, Glatt M, Weber F, Mertelsmann R, Kanz L. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors [see comment citation in Medline]. Blood 1994;83:636-40.
36. Embleton MJ, Byers VS, Lee HM, Scannon P, Blackhall NW, Baldwin RW. Sensitivity and selectivity of ricin toxin A chain-monoclonal antibody 791T/36 conjugates against human tumor cell lines. Cancer Res 1986; 46:5524-8.
37. Laurent G, Kuhlein E, Casellas P, Canat X, Carayon P, Poncelet P, et al. Determination of sensitivity of fresh leukemia cells to immunotoxins. Cancer Res 1986;46:2289-94.
38. Pai LH, Bookman MA, Ozols RF, Young RC, Smith JW 2d, Longo DL, et al. Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer [see comment citation in Medline]. J Clin Oncol 1991;9:2095-103.
39. Epstein C, Lynch T, Shefner J, Wen P, Maxted D, Braman V, et al. Use of the immunotoxin N901-blocked ricin in patients with small-cell lung cancer. Int J Cancer Suppl 1994;8:57-9.